Answers are grounded in this paper and cite their sources.
Respiratory syncytial virus (RSV) infection is the leading cause of lower respiratory tract infection in young children, with significant numbers of premature infants and those with other risk factors requiring hospitalization in Canada each year. Palivizumab, an RSV-specific monoclonal antibody, can reduce the hospitalization rate and severity of illness for a small group of high-risk or premature infants during their first RSV season. The present statement reviews the published literature and provides recommendations regarding its use in premature and other at-risk infants, for Canadian physicians.
No takes yet. Share an insight, caveat, or question.
Lindy Samson (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: